Testosterone Levels and Cutibacterium

Sponsor
University of Washington (Other)
Overall Status
Recruiting
CT.gov ID
NCT05030220
Collaborator
(none)
300
1
42
7.1

Study Details

Study Description

Brief Summary

Phase 1: In 51 patients undergoing shoulder arthroplasties, total serum testosterone, free testosterone and sex hormone binding globulin levels obtained in the clinic before surgery were correlated with the levels of Cutibacterium on the skin in clinic, in the operating room prior to surgery, and in the skin incision.

Phase 2: The investigators wish to determine if preoperative serum testosterone levels are associated with risk for shoulder PJI (periprosthetic joint infection) in patients undergoing primary shoulder arthroplasty. Also to determine if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Phase 1: 51 patients having elective shoulder arthroplasty were offered the opportunity to participate, consented and enrolled in this prospective clinical cohort study.

    At a preoperative clinic visit, basic demographic information was collected along with the patient's response to a question about taking supplemental testosterone. A swab of the unprepared skin over the area of the intended surgical incision was obtained and sent for culture. At this clinic visit, a sample of the patient's blood was also obtained and submitted to our clinical laboratory for the levels of total serum testosterone, sec hormone binding globulin (SHBG), and free testosterone.

    Immediately before surgery, another swab of the unprepared skin over the area of the intended surgical incision was once again obtained and sent for culture. After incision, a swab of the freshly incised dermis was obtained and sent for culture.

    All 3 swabs that were obtained were observed for 21 days. The investigators analyzed the cultures to determine the presence and load of bacteria using a semiquantitative method, known as the Cutibacterium specimen value (SpCuV)

    Phase 2: This phase will also involve a onetime pre-operative testosterone serum test. If the subject consents to participate, this additional sample of blood will be collected for a testosterone serum test during the routine pre-operative blood draw that all patients have before a shoulder arthroplasty regardless of research participation. The investigators will include cultures such as skin swabs taken at pre-operative clinic appointments, skin swabs taken at the time of surgery, incision swabs taken at the time of surgery, and discarded tissue from surgery using our standard protocol for specimens. For this study's outcome measures, the investigators will record the culture results from those clinical specimens and compare them to the testosterone serum test. Some subjects may also be a part of a long term follow-up study and the follow-up data (self-reported outcome measures, etc.) from that study will be included for analysis for those patients.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Association Between Serum Testosterone Levels and Cutibacterium Culture Positivity During Shoulder Arthroplasty
    Actual Study Start Date :
    Jul 1, 2020
    Anticipated Primary Completion Date :
    Jan 1, 2023
    Anticipated Study Completion Date :
    Jan 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Phase 1

    51 subjects with serum levels of testosterone, free testosterone, and sex hormone binding globulin as well as the SpCuV from the cultures obtained in clinic, immediately pre-operative skin cultures, and incised wound cultures.

    Phase 2

    Subjects enrolled to help determine if preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty and if preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty.

    Outcome Measures

    Primary Outcome Measures

    1. Serum testosterone [At pre-operative clinic appointment, typically within 30 days prior to surgery]

    2. Free testosterone [At pre-operative clinic appointment, typically within 30 days prior to surgery]

    3. sex hormone binding globulin [At pre-operative clinic appointment, typically within 30 days prior to surgery]

    4. Cutibacterium specimen value [Skin swab at pre-operative clinic appointment, typically within 30 days prior to surgery]

    5. Cutibacterium specimen value [Skin swab immediately pre-operative]

    6. Cutibacterium specimen value [Freshly incised dermis of surgical wound]

    7. Preoperative serum testosterone levels are associated with risk for shoulder PJI in patients undergoing primary shoulder arthroplasty. [Up to 20 years after surgery]

    8. Preoperative serum testosterone levels are predictive of bacterial load of deep tissue cultures taken at the time of revision shoulder arthroplasty in patients undergoing primary shoulder arthroplasty [21 days after surgery]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 89 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Phase 1 Inclusion Criteria:
    • Patients having elective shoulder arthroplasty
    Phase 1 Exclusion Criteria:
    • history of shoulder septic arthritis

    • antibiotic use within 3 months prior to surgery

    • recent treatment for acne

    • Lacked fluency in English

    Phase 2 Inclusion Criteria:
    • Patients having elective shoulder arthroplasty
    Phase 2 Exclusion Criteria:
    • Lacked fluency in English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Washington Seattle Washington United States 98195

    Sponsors and Collaborators

    • University of Washington

    Investigators

    • Principal Investigator: Jason E Hsu, MD, University of Washington

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jason Hsu, Associate Professor, School of Medicine, University of Washington
    ClinicalTrials.gov Identifier:
    NCT05030220
    Other Study ID Numbers:
    • STUDY00009200
    First Posted:
    Sep 1, 2021
    Last Update Posted:
    Sep 1, 2021
    Last Verified:
    Aug 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jason Hsu, Associate Professor, School of Medicine, University of Washington

    Study Results

    No Results Posted as of Sep 1, 2021